EGFR and cancer: drug category revealed that drugs with similar targets tend to be clustered together, and drugs targeting ErbB2, 3, and 4 were more potent in cancer cell lines with high ErbB2 expression as compared with drugs targeting EGFR (ErbB1) alone (Figure 2D).